Nimustine (ACNU) is an alkylating agent of the nitrosourea and can be an antineoplastic agent in dogs. But, there has been no report on its dose-limiting toxicity (DLT) in dogs. This study was a phase I dose-escalation clinical trial to determine the maximum tolerated dose (MTD) and DLT of ACNU in tumor-bearing dogs. The starting dosage was 25 mg/m2, and subsequent dosages were administered in increments of 5 mg/m2 in cohort of 3 dogs. Eight dogs were included, the MTD was determined to be 25 mg/m2, DLT was neutropenia, and the optimal interval was considered to be 21 days. The data herein provide a basis for the subsequent phase II trial of ACNU in dogs. © 2014 The Japanese Society of Veterinary Science.
CITATION STYLE
Takahashi, M., Goto-Koshino, Y., Fukushima, K., Kanemoto, H., Nakashima, K., Fujino, Y., … Tsujimoto, H. (2014). Phase I dose-escalation study of Nimustine in tumor-bearing dogs. Journal of Veterinary Medical Science. Japanese Society of Veterinary Science. https://doi.org/10.1292/jvms.13-0345
Mendeley helps you to discover research relevant for your work.